You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 27, 2025

Agios Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Agios Pharms Inc
International Patents:156
US Patents:9
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Agios Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-003 Feb 17, 2022 RX Yes Yes 10,632,114 ⤷  Try for Free ⤷  Try for Free
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-001 Feb 17, 2022 RX Yes No 11,878,049 ⤷  Try for Free ⤷  Try for Free
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-002 Feb 17, 2022 RX Yes No 11,878,049 ⤷  Try for Free ⤷  Try for Free
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-002 Feb 17, 2022 RX Yes No 11,254,652 ⤷  Try for Free Y Y ⤷  Try for Free
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-002 Feb 17, 2022 RX Yes No 9,193,701 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Agios Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2448582 301230 Netherlands ⤷  Try for Free PRODUCT NAME: MITAPIVAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER MITAPIVATSULFAAT; REGISTRATION NO/DATE: EU/1/22/1662 20221110
2448582 CR 2023 00014 Denmark ⤷  Try for Free PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110
2448582 PA2023513 Lithuania ⤷  Try for Free PRODUCT NAME: MITAPIVATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC MITAPIVATO SULFATAS; REGISTRATION NO/DATE: EU/1/22/1662 20221109
2448582 C202330019 Spain ⤷  Try for Free PRODUCT NAME: MITAPIVAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR SULFATO DE MITAPIVAT; NATIONAL AUTHORISATION NUMBER: EU/1/22/1662; DATE OF AUTHORISATION: 20221109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1662; DATE OF FIRST AUTHORISATION IN EEA: 20221109
2448582 122023000025 Germany ⤷  Try for Free PRODUCT NAME: MITAPIVAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE MITAPIVATSULFAT; REGISTRATION NO/DATE: EU/1/22/1662 20221109
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Agios Pharmaceuticals Inc – Market Position, Strengths & Strategic Insights

Agios Pharmaceuticals Inc. has emerged as a significant player in the biopharmaceutical industry, carving out a niche in the field of cellular metabolism and rare genetic diseases. This comprehensive analysis delves into Agios's market position, strengths, and strategic insights, providing a detailed overview of the company's competitive landscape.

Market Position of Agios Pharmaceuticals

Agios Pharmaceuticals has established itself as a leader in the development of novel therapies targeting cellular metabolism and rare genetic diseases. The company's focus on innovative approaches to drug discovery and development has allowed it to create a unique position in the competitive biopharmaceutical landscape[3].

Specialization in Cancer Metabolism

One of Agios's key differentiators is its deep expertise in cancer metabolism. By targeting specific metabolic vulnerabilities in cancer cells, Agios has developed therapies that have the potential to be more effective and less toxic than traditional cancer treatments[3]. This specialized knowledge has enabled the company to carve out a distinct niche in the oncology market.

Strong Financial Position

Agios boasts a robust financial foundation, which significantly strengthens its market position. As of September 30, 2024, the company reported cash, cash equivalents, and marketable securities of $1.7 billion[1]. This strong cash reserve provides Agios with the flexibility to invest in research and development, pursue strategic opportunities, and weather potential market uncertainties.

One of Agios's key strengths is its robust financial position. The company boasts a cash reserve of approximately $1.7 billion as of the third quarter of 2024[2].

Agios's Competitive Advantages

Innovative Research and Development

Agios's commitment to cutting-edge research and development is a cornerstone of its competitive advantage. The company invests heavily in scientific innovation, enabling it to build a robust pipeline of drug candidates at various stages of development[3].

Strategic Partnerships

Agios has forged strategic partnerships with leading academic institutions, research organizations, and pharmaceutical companies. These collaborations enhance the company's research capabilities, provide access to valuable resources, and accelerate the development of its drug candidates[3].

Strong Patent Portfolio

A robust patent portfolio protects Agios's intellectual property, providing a significant competitive edge in the market. This protection allows the company to commercialize its innovations and generate revenue without immediate threat from competitors[3].

Experienced Leadership Team

Agios is led by a team of seasoned executives and scientists with a proven track record in the biopharmaceutical industry. This experienced leadership provides strategic direction and guidance for the company's growth and success[3].

Product Portfolio and Pipeline

PYRUKYND® (Mitapivat)

PYRUKYND® is Agios's lead product, a first-in-class pyruvate kinase R (PKR) activator. In the third quarter of 2024, PYRUKYND® generated net revenue of $9.0 million, demonstrating its commercial potential[1].

Robust Pipeline

Agios has a diverse pipeline of potential drug candidates targeting various types of cancer and rare genetic diseases. This pipeline is supported by the company's cutting-edge research and development capabilities[3].

Recent Developments and Future Prospects

Completion of Phase 3 RISE UP Study

Agios recently completed enrollment for the Phase 3 RISE UP study of mitapivat in Sickle Cell Disease. Topline data from this 52-week study is expected in late 2025, potentially opening up new market opportunities for the company[1].

FDA Approval of Vorasidenib

The FDA's approval of Servier's vorasidenib for the treatment of IDH-mutant diffuse glioma resulted in significant financial gains for Agios. The company received a $200 million milestone payment from Servier and a $905 million payment from Royalty Pharma[1].

Expansion into New Markets

Agios has entered into a distribution agreement with NewBridge Pharmaceuticals to advance the commercialization of PYRUKYND® in the Gulf Cooperation Council (GCC) region. This move demonstrates the company's commitment to global expansion and market penetration[1].

Challenges and Opportunities

Challenges

  1. Rapidly Evolving Regulatory Landscape: Agios must navigate an ever-changing regulatory environment, ensuring compliance while adapting its strategies to overcome potential hurdles[3].

  2. Increasing Competition: The biopharmaceutical industry is becoming increasingly crowded, requiring Agios to continually innovate and differentiate itself from competitors[3].

  3. Market Access and Reimbursement: Securing market access and reimbursement for its products remains a challenge, as payers become more stringent in their coverage decisions[3].

Opportunities

  1. Expansion of Product Portfolio: Agios has the opportunity to leverage its expertise in cancer metabolism to develop novel treatments for a wide range of oncology indications[3].

  2. Global Expansion: Through strategic partnerships and collaborations, Agios can access new markets and technologies, accelerating the development and commercialization of its therapies[3].

  3. Personalized Medicine: Agios can capitalize on the growing demand for personalized medicine by leveraging its expertise in cancer metabolism to develop targeted therapies tailored to individual patients[3].

Strategic Vision: "Agios 2025"

Agios has outlined its strategic vision for growth over the next six years, dubbed "Agios 2025". This vision includes ambitious goals for product development and market expansion[8].

Key Milestones

By the end of 2025, Agios aims to achieve the following milestones:

  1. Four marketed medicines discovered and developed at Agios
  2. At least eight approved indications
  3. At least six molecules in clinical development
  4. A broad research pipeline[8]

Financial Performance and Market Outlook

Strong Financial Health

Agios maintains a strong financial health score of 2.77 (rated as GOOD), suggesting solid operational fundamentals. The company's stock is currently trading below its Fair Value, potentially presenting an opportunity for investors[7].

Market Performance

Agios has demonstrated impressive momentum with an 88.41% year-to-date return as of December 2024, reflecting growing investor confidence in its strategic direction. The company's market capitalization stands at $2.3 billion, with analysts maintaining a consensus buy recommendation[2].

Competitive Landscape and Industry Trends

Key Competitors

Agios faces competition from several major players in the biopharmaceutical industry, including Celgene, Merck, and Roche[5].

Industry Trends

The cancer metabolism industry is seeing growing interest in targeting metabolic pathways for cancer treatment. Agios's focus on this area positions it well to capitalize on this trend[5].

Future Outlook and Growth Strategies

Continued Investment in R&D

Agios plans to continue investing in cutting-edge research and development to drive innovation and bring new therapies to market[3].

Exploration of New Therapeutic Areas

The company is exploring new therapeutic areas beyond oncology, leveraging its expertise in metabolism to address a broader range of diseases[3].

Enhancing Operational Efficiency

Agios aims to optimize its operations to improve productivity and reduce costs, ensuring sustainable growth in the long term[3].

Key Takeaways

  1. Agios Pharmaceuticals has established a strong market position in the biopharmaceutical industry, particularly in the field of cancer metabolism and rare genetic diseases.

  2. The company's competitive advantages include its expertise in cancer metabolism, strong R&D pipeline, strategic partnerships, and robust financial position.

  3. Agios's lead product, PYRUKYND® (mitapivat), is showing promising commercial potential, with net revenue of $9.0 million in Q3 2024.

  4. The company faces challenges such as a rapidly evolving regulatory landscape and increasing competition but also has significant opportunities for growth through product portfolio expansion and global market penetration.

  5. Agios's "Agios 2025" strategic vision outlines ambitious goals for product development and market expansion over the next six years.

  6. The company's strong financial health and market performance indicate positive investor sentiment and potential for future growth.

  7. Continued investment in R&D, exploration of new therapeutic areas, and focus on operational efficiency are key components of Agios's future growth strategy.

FAQs

  1. What is Agios Pharmaceuticals' primary focus? Agios Pharmaceuticals primarily focuses on developing novel therapies targeting cellular metabolism and rare genetic diseases, with a particular emphasis on cancer metabolism.

  2. What is PYRUKYND® and why is it significant for Agios? PYRUKYND® (mitapivat) is Agios's lead product, a first-in-class pyruvate kinase R (PKR) activator. It's significant because it demonstrates the company's ability to bring innovative therapies to market and generate revenue.

  3. How does Agios's financial position compare to its competitors? Agios maintains a strong financial position with $1.7 billion in cash, cash equivalents, and marketable securities as of September 2024, which provides it with significant flexibility for investments and strategic moves.

  4. What are the main challenges facing Agios Pharmaceuticals? Key challenges include navigating a rapidly evolving regulatory landscape, increasing competition in the biopharmaceutical industry, and securing market access and reimbursement for its products.

  5. What is the "Agios 2025" strategic vision? "Agios 2025" is the company's strategic plan for growth over the next six years. It aims to have four marketed medicines, at least eight approved indications, six molecules in clinical development, and a broad research pipeline by the end of 2025.

Sources cited: [1] https://investor.agios.com/news-releases/news-release-details/agios-reports-business-highlights-and-third-quarter-2024 [2] https://www.investing.com/news/swot-analysis/agios-pharmaceuticals-swot-analysis-mitapivat-potential-drives-stock-outlook-93CH-3779765 [3] https://canvasbusinessmodel.com/blogs/growth-strategy/agios-pharmaceuticals-growth-strategy [5] https://canvasbusinessmodel.com/blogs/competitors/agios-pharmaceuticals-competitive-landscape [7] https://uk.investing.com/news/swot-analysis/agios-pharmaceuticals-swot-analysis-stock-outlook-amid-scd-market-shifts-93CH-3834464 [8] https://investor.agios.com/news-releases/news-release-details/agios-announces-agios-2025-strategic-vision-and-highlights-2020

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.